AbCellera Biologics (ABCL) News Today $2.42 +0.03 (+1.26%) Closing price 04:00 PM EasternExtended Trading$2.41 -0.01 (-0.41%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period AbCellera price target raised to $5 from $4 at KeyBancApril 17 at 10:53 AM | markets.businessinsider.comAbCellera: Attractively Priced But A Catalyst Is NeededApril 16 at 11:59 PM | seekingalpha.comKeyBanc Remains a Buy on AbCellera Biologics (ABCL)April 16 at 7:58 AM | theglobeandmail.comFederated Hermes Inc. Lowers Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)Federated Hermes Inc. reduced its holdings in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 59.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 916,237 shares of the company's stock after selApril 15 at 3:57 AM | marketbeat.com281,795 Shares in AbCellera Biologics Inc. (NASDAQ:ABCL) Purchased by ExodusPoint Capital Management LPExodusPoint Capital Management LP bought a new position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 281,795 shares of the company's stock, valued atApril 13, 2025 | marketbeat.com1,284,533 Shares in AbCellera Biologics Inc. (NASDAQ:ABCL) Purchased by Norges BankNorges Bank bought a new position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 1,284,533 shares of the company's stock, valued at approximately $3,764,000. Norges Bank owned aApril 13, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading 8.8% Higher - Still a Buy?April 13, 2025 | americanbankingnews.comAbCellera Biologics (NASDAQ:ABCL) Hits New 52-Week Low - Should You Sell?AbCellera Biologics (NASDAQ:ABCL) Hits New 12-Month Low - Here's What HappenedApril 9, 2025 | marketbeat.comAbCellera to Participate at Upcoming Investor Conferences in May and JuneApril 8, 2025 | financialpost.comAbCellera Biologics (NASDAQ:ABCL) Shares Up 5.9% - What's Next?AbCellera Biologics (NASDAQ:ABCL) Trading 5.9% Higher - Should You Buy?April 4, 2025 | marketbeat.comDnB Asset Management AS Has $895,000 Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)DnB Asset Management AS increased its position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 424.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 305,579 shares of the company's stApril 4, 2025 | marketbeat.comAbCellera to Report First Quarter 2025 Financial Results on May 8, 2025April 3, 2025 | businesswire.comAbCellera Biologics (NASDAQ:ABCL) Sets New 1-Year Low - Here's WhyAbCellera Biologics (NASDAQ:ABCL) Hits New 52-Week Low - Time to Sell?April 3, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Down 4.1% - Here's What HappenedAbCellera Biologics (NASDAQ:ABCL) Shares Down 4.1% - Time to Sell?March 26, 2025 | marketbeat.comAbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025March 25, 2025 | businesswire.comGuardian Partners Inc. Acquires New Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)Guardian Partners Inc. acquired a new stake in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,786,414 shares of the company's stock, valuMarch 24, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading Down 3.4% - Here's WhyAbCellera Biologics (NASDAQ:ABCL) Shares Down 3.4% - Time to Sell?March 18, 2025 | marketbeat.comAbCellera: Burning Cash, Searching For 'Blockbusters'March 15, 2025 | seekingalpha.comAbCellera Biologics (NASDAQ:ABCL) Hits New 12-Month Low - Here's WhyAbCellera Biologics (NASDAQ:ABCL) Sets New 52-Week Low - Here's What HappenedMarch 11, 2025 | marketbeat.comWhat is Bloom Burton's Estimate for ABCL FY2025 Earnings?AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Research analysts at Bloom Burton dropped their FY2025 earnings per share estimates for AbCellera Biologics in a report issued on Monday, March 3rd. Bloom Burton analyst D. Martin now anticipates that the company will post earnings per shareMarch 7, 2025 | marketbeat.comQ1 Earnings Estimate for ABCL Issued By Bloom BurtonAbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Equities researchers at Bloom Burton issued their Q1 2025 EPS estimates for AbCellera Biologics in a research report issued to clients and investors on Monday, March 3rd. Bloom Burton analyst D. Martin expects that the company will earn ($0.1March 6, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Given "Hold" Rating at BenchmarkBenchmark restated a "hold" rating on shares of AbCellera Biologics in a report on Monday.March 3, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Analyst DowngradeAbCellera Biologics (NASDAQ:ABCL) Shares Gap Down Following Analyst DowngradeMarch 1, 2025 | marketbeat.comStifel Nicolaus Issues Pessimistic Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock PriceStifel Nicolaus dropped their target price on AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Friday.March 1, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Reaches New 52-Week Low on Analyst DowngradeAbCellera Biologics (NASDAQ:ABCL) Reaches New 1-Year Low Following Analyst DowngradeMarch 1, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPSAbCellera Biologics (NASDAQ:ABCL - Get Free Report) posted its earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04. AbCellera Biologics had a negative net margin of 533.32% and a negative return on equity of 15.73%.February 28, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Posts Earnings Results, Beats Expectations By $0.04 EPSAbCellera Biologics (NASDAQ:ABCL - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.04. AbCellera Biologics had a negative return on equity of 15.73% and a negative net margin of 533.32%.February 28, 2025 | marketbeat.comAbCellera price target lowered to $10 from $12 at StifelFebruary 28, 2025 | markets.businessinsider.comAbCellera Biologics (ABCL) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | msn.comAbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comAbCellera files automatic mixed securities shelfFebruary 27, 2025 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on AbCellera Biologics (ABCL)February 27, 2025 | markets.businessinsider.comAbCellera Reports Full Year 2024 Business ResultsFebruary 27, 2025 | businesswire.comWhat To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 EarningsFebruary 26, 2025 | finance.yahoo.comAbCellera Biologics (ABCL) Projected to Post Earnings on ThursdayAbCellera Biologics (NASDAQ:ABCL) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=659273)February 25, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Down 8.5% - Here's What HappenedAbCellera Biologics (NASDAQ:ABCL) Stock Price Down 8.5% - Here's WhyFebruary 21, 2025 | marketbeat.comAbCellera Biologics (ABCL) to Release Quarterly Earnings on ThursdayAbCellera Biologics (NASDAQ:ABCL) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=659273)February 20, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - Here's WhyAbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - Time to Buy?February 19, 2025 | marketbeat.comAbCellera COO transitions to Chief Technology OfficerFebruary 18, 2025 | markets.businessinsider.comOne AbCellera Biologics Insider Raised Their Stake In The Previous YearFebruary 18, 2025 | finance.yahoo.comAbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. reduced its stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 5.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,236,465 shares of the company's stock aftFebruary 18, 2025 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Short Interest UpdateAbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) saw a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 18,430,000 shares, an increase of 6.8% from the January 15th total of 17,260,000 shares. Approximately 8.3% of the shares of the company are sold short. Based on an average trading volume of 3,150,000 shares, the days-to-cover ratio is presently 5.9 days.February 16, 2025 | marketbeat.comAbCellera Biologics (ABCL) to Release Quarterly Earnings on TuesdayAbCellera Biologics (NASDAQ:ABCL) will be releasing earnings after the market closes on Tuesday, February 18, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=512046)February 16, 2025 | marketbeat.comAbCellera to Participate at Upcoming Investor Conferences in MarchFebruary 11, 2025 | financialpost.comAbCellera to Participate at Upcoming Investor Conferences in MarchFebruary 11, 2025 | businesswire.comAbCellera Biologics (ABCL) to Release Earnings on TuesdayAbCellera Biologics (NASDAQ:ABCL) will be releasing earnings after the market closes on Tuesday, February 18, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=512046)February 11, 2025 | marketbeat.comMoloney Securities Asset Management LLC Makes New Investment in AbCellera Biologics Inc. (NASDAQ:ABCL)Moloney Securities Asset Management LLC purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 90,400 shares of the company'February 11, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading Down 5% - Here's What HappenedAbCellera Biologics (NASDAQ:ABCL) Shares Down 5% - Time to Sell?February 7, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading Down 4% - What's Next?AbCellera Biologics (NASDAQ:ABCL) Trading Down 4% - Time to Sell?January 28, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Up 18.8% - Still a Buy?AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 18.8% - Time to Buy?January 24, 2025 | marketbeat.com Remove Ads Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address ABCL Media Mentions By Week ABCL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABCL News Sentiment▼0.760.80▲Average Medical News Sentiment ABCL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABCL Articles This Week▼83▲ABCL Articles Average Week Remove Ads Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MorphoSys News Today SpringWorks Therapeutics News Today Crinetics Pharmaceuticals News Today Catalyst Pharmaceuticals News Today Protagonist Therapeutics News Today Viking Therapeutics News Today Scholar Rock News Today Immunovant News Today HUTCHMED News Today Alvotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABCL) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABCL Stock Free ABCL Stock Alerts